

## Special Issue

# Vaccines to Reduce Antimicrobial Resistance to Bacterial Pathogens

### Message from the Guest Editors

The rise of antimicrobial resistance has led to the inefficacy of drugs and persistent infections, which consequently increase the risk of severe illness and the spread of disease. To combat antimicrobial resistance, an integrated approach that includes vaccines and antibiotics is needed. Vaccines play a crucial role in preventing infections caused by resistant bacteria, thereby reducing the reliance on antibiotics and slowing the spread of resistance. This Special Issue aims to provide an overview of advancements in the development of bacterial vaccines targeting antimicrobial-resistant pathogens. The scope of this Special Issue includes the following topics: (i) novel technologies and approaches to the production of bacteria vaccines, (ii) vaccination-induced immune responses, (iii) mucosal vaccines and vaccination, and (iv) the use of vaccines as tools for combating antimicrobial resistance. We welcome the submission of research papers, short communications, and reviews related to these topics.

---

### Guest Editors

Dr. Miriam Moscoso

Dr. Astrid Pérez

Dr. Eva Gato

---

### Deadline for manuscript submissions

31 December 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/213927](https://mdpi.com/si/213927)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).